Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. trimmed its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 9.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 3,700,000 shares of the company’s stock after selling 395,000 shares during the period. Taysha Gene Therapies comprises 39.1% of Tybourne Capital Management HK Ltd.’s investment portfolio, making the stock its biggest position. Tybourne Capital Management HK Ltd. owned approximately 1.36% of Taysha Gene Therapies worth $12,099,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of TSHA. Profund Advisors LLC grew its holdings in shares of Taysha Gene Therapies by 100.6% in the third quarter. Profund Advisors LLC now owns 53,366 shares of the company’s stock valued at $175,000 after acquiring an additional 26,767 shares in the last quarter. Principal Financial Group Inc. grew its stake in Taysha Gene Therapies by 33.6% in the 3rd quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock valued at $53,000 after purchasing an additional 4,091 shares during the period. New York State Common Retirement Fund grew its stake in Taysha Gene Therapies by 220.4% in the 3rd quarter. New York State Common Retirement Fund now owns 67,600 shares of the company’s stock valued at $221,000 after purchasing an additional 46,500 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $1,890,000. Finally, ST Germain D J Co. Inc. raised its stake in shares of Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares during the period. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $4.61 on Tuesday. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -13.97 and a beta of 1.01. The company’s fifty day simple moving average is $5.11 and its two-hundred day simple moving average is $4.21. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Insiders Place Their Bets

In other news, CFO Kamran Alam sold 78,968 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total value of $375,098.00. Following the completion of the transaction, the chief financial officer directly owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. This trade represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This represents a 20.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 968,795 shares of company stock worth $4,518,093 in the last quarter. 3.78% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on TSHA. Wells Fargo & Company lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Citizens Jmp lifted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. The Goldman Sachs Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.